Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in XXXX with Operable @entity5 : Preliminary Results of a Prospective Randomized Multicenter Study.

@entity1 @entity138 @entity5 @entity1168 @entity1349
The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of @entity5 ( @entity5 ) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative @entity1168 ( @entity1168 ) BT. In this article we evaluate the efficiency of preoperative @entity1168 BT by the rate of pathologic complete remission (pCR) in the first 185 @entity1 enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, @entity1 received 2x8Gy preoperative intracavitary @entity1168 BT, while in arm B no preoperative treatment was given. In both arms @entity1 underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative @entity1168 BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the @entity5 was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative @entity138 (p=0.02). There was no significant difference in the @entity5 control (LTC), distant metastases free survival (DMFS) and @entity1349 ( @entity1349 ) between the two arms. According to our preliminary results preoperative intracavitary @entity1168 BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in @entity1 with @entity5 . Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and @entity1349 .
